Study of Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat B Cell Lymphoma Except for Diffuse Large B Cell Lymphoma

PHASE2UnknownINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

December 31, 2014

Conditions
Non-Hodgkin Lymphoma
Interventions
DRUG

Busulfan, etoposide, cytarabine, and melphalan

Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day

Trial Locations (5)

614-735

RECRUITING

Inje University Busan Paik Hospital, Inje University College of Medicine, Busan

110-744

RECRUITING

Seoul National University Hospital, Seoul National University College of Medicine, Seoul

120-752

RECRUITING

Severance Hospital, Yonsei University College of Medicine, Seoul

138-736

RECRUITING

Asan Medical Center, University of Ulsan College of Medicine, Seoul

682-714

RECRUITING

Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Inje University

OTHER

collaborator

Severance Hospital

OTHER

collaborator

Asan Medical Center

OTHER

collaborator

Ulsan University Hospital

OTHER

lead

Seoul National University Hospital

OTHER